The Medicines and Healthcare products Regulatory Agency (MHRA) published a Drug Safety Update on 24 February 2026 reporting that a falsified presentation of Mounjaro (tirzepatide) KwikPen 15 mg solution for injection had entered UK supply through a single online pharmacy.[1] Five pens had been identified at the time of publication. Recovered devices contained tirzepatide on testing, but the pens did not meet the quality or sterility standards of the licensed product and showed a consistent mechanical fault.[1][2]

This is a supply-integrity finding about a UK-authorised dual glucose-dependent insulinotropic polypeptide (GIP) / glucagon-like peptide-1 (GLP-1) receptor agonist. It is not a new efficacy result, and it does not reclassify tirzepatide’s UK legal status. Mounjaro remains a prescription-only medicine (POM) under the Human Medicines Regulations 2012.[4][5] Peptide Data does not advise personal use of tirzepatide, licensed or otherwise. The account below reports what the regulator published.

1. Product identification

The falsified pens are labelled as Mounjaro KwikPen 15 mg solution for injection in a pre-filled pen and carry batch number D873576.[1] The MHRA states that all 15 mg pens with this batch number are falsified. The same batch number is legitimate for genuine Mounjaro KwikPen 7.5 mg; pens at that strength are not implicated.[1][2]

Eli Lilly and Company Limited informed the MHRA that the batch number and expiry date on the legitimate pack match a genuine 7.5 mg presentation, whereas the falsified packaging presents the product as 15 mg.[1] The MHRA is explicit that the printed expiry date (October 2026) is not a useful discriminator: identification rests on strength plus batch number only.[1]

The issue came to light because of faults with the pens. In all but one of the cases reviewed, the dose knob came off during use.[1][2] All pens identified to date have had a faulty mechanism. The MHRA advises that doses should not be extracted from any defective pen — a quality-control instruction about a failed device, not a use protocol.[1]

2. What testing showed — and what it did not

Laboratory testing of recovered falsified pens confirmed that they contain tirzepatide.[1] That result should not be read as reassurance. The MHRA states that the pens are not of the quality and safety standards of legitimate pens and are not safe to use, because the manufacturing history is unknown and sterility cannot be assumed.[1] As an injectable product, a non-sterile fill carries a theoretical infection risk; hypersensitivity reactions are also listed as a concern.[1]

At publication the MHRA had not received reports of patient harm that required treatment after use of the falsified medicine.[1][2] That statement is a pharmacovigilance snapshot, not a demonstration of safety. Five identified units is a small seized sample; it does not bound how many pens were dispensed, nor how the fill was manufactured.

3. Supply channel and GPhC action

The MHRA names a single supply point: The Private Pharmacy Clinic, an online pharmacy in Birmingham.[1] The General Pharmaceutical Council (GPhC) served a notice of conditions on that premises (registration 9012397) with effect from 19 February 2026, under section 74D of the Medicines Act 1968.[3] The published summary states that the pharmacy had not met the Standards for Registered Pharmacies in consecutive inspections, could not show that restricted activities had always had the required Responsible Pharmacist oversight, and that there was evidence it had not taken adequate action to minimise risk when quality concerns were raised.[3] The condition imposed is that the pharmacy must not obtain, sell or supply any prescription-only medicines or medical devices.[3] The MHRA notes that its own investigation is continuing.[1]

Healthcare professionals are instructed not to supply 15 mg pens with batch D873576, to quarantine remaining stock of the affected strength and batch, and to return it to the supplier.[1] Suspected adverse reactions to tirzepatide, or suspected defective pens, are to be reported through the Yellow Card scheme.[1]

4. UK legal frame

Tirzepatide as Mounjaro is a UK-authorised POM. Authorisation and pharmacy supply sit under the Human Medicines Regulations 2012 and the Medicines Act 1968.[5] Falsified medicines in the licensed channel are a criminal and regulatory matter; they are not a grey-area research-chemical listing. The MHRA’s standing public guidance on GLP-1 medicines reiterates that these products are prescription-only, that a consultation must precede private supply, and that purchase from unregulated sellers — including social media and premises without a prior healthcare-professional consultation — is both a safety risk and unlawful.[4]

That guidance also records that legitimate licensed GLP-1 products are supplied as pre-filled injection pens or as tablets, and that powders in vials requiring reconstitution are not authorised presentations of these medicines.[4] The present DSU is narrower: it concerns pens that mimic a licensed pack, not unlicensed vials. The two problems are related only in that both sit outside the quality system the marketing authorisation assumes.

Section 74D conditions on a registered pharmacy are an occupancy-level restriction on the premises, distinct from a marketing-authorisation variation or a class-wide SmPC change. Nothing in this DSU amends the licensed indications, the SmPC pancreatitis warnings issued on 29 January 2026, or NICE technology appraisal TA1026 on tirzepatide for overweight and obesity.[1][4]

5. What this does not tell researchers

Unlicensed tirzepatide sold as a research chemical is not the product named in this Drug Safety Update. The DSU is about a presentation that copied licensed packaging and still failed mechanical and sterility standards.[1] It is not a head-to-head quality study of research-grade material, and it should not be cited as one.

The finding is nonetheless relevant to anyone reading the peptide literature. Even a product designed to look like a licensed dual GIP/GLP-1 pen — recovered from a registered pharmacy channel, containing tirzepatide on assay — was judged unsafe because manufacture and sterility were unverifiable.[1] That is a quality-system conclusion, not a statement about receptor pharmacology. It does not support treating grey-market vials, lyophilised powders, or social-media listings as equivalent to, or safer than, the authorised presentation.

Peptide Data frames all unlicensed peptides as research compounds, not for human consumption. Nothing in the MHRA text, and nothing in this article, is dosing, self-administration, or personal-use advice.

6. Place in the recent MHRA GLP-1 record

This DSU sits alongside, and is distinct from, other 2025–2026 MHRA communications on the class:

  • 29 January 2026: strengthened SmPC/PIL warnings on acute pancreatitis, including rare necrotising and fatal cases, across UK-authorised GLP-1 and dual GIP/GLP-1 receptor agonists.[2][4]
  • Semaglutide-specific NAION (non-arteritic anterior ischaemic optic neuropathy) precautions, with urgent ophthalmological referral if sudden vision loss is reported.[2][4]
  • Earlier class communications on pulmonary aspiration risk around anaesthesia or deep sedation, and on prescription-only supply.[4]

Those are product-information and clinical-vigilance actions. The February 2026 Mounjaro pen DSU is a falsified-medicine and pharmacy-enforcement action. Conflating them would overstate what is known about either.

7. Limitations

The public record at 24–25 February 2026 is a regulator snapshot: five pens, one named pharmacy, one batch/strength pair, confirmatory assay for tirzepatide, no sterility assurance, no reports of treatment-requiring harm, and an ongoing MHRA investigation.[1][2] Impurity profile, fill volume accuracy, endotoxin, and the origin of the devices have not been published. Subsequent Yellow Card reports, GPhC fitness-to-practise outcomes, or a wider batch notification could change the picture. This article will need revision if the MHRA issues a follow-up that expands or contracts the affected set.

Research-use framing. Tirzepatide is a licensed POM in the UK when supplied as Mounjaro under a valid prescription. Unlicensed tirzepatide is a research compound. Peptide Data does not claim that tirzepatide treats, cures or prevents any condition, and does not provide consumption or self-administration advice.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.